Galactosyl derivative of Nω-nitro-L-arginine: Study of antiproliferative activity on human thyroid follicular carcinoma cells

Journal of Cellular Physiology

Volumn 221, Issue 2, 2009, Pages 440-447

  Melisi, Daniela ^a   Rosso, Francesco ^b   Curcio, Annalisa ^a   Tortora, Carla ^b   Nieddu, Maria ^c   Marino, Gerardo ^b   Lettieri, Maria ^b   Grimaldi, Anna ^b   Luongo, Elvira ^a   Romano, Simona ^a   Romano, Maria Fiammetta ^a   Boatto, Gianpiero ^c   Abignente, Enrico ^a   Barbarisi, Alfonso ^b   Rimoli, Maria Grazia ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF SASSARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GALACTOSE; INDUCIBLE NITRIC OXIDE SYNTHASE; N OMEGA NITROARGININE DEXTRO GALACTOS 6' YL ESTER; N(G) NITROARGININE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PRODRUG; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NITROBLUE TETRAZOLIUM TEST; PRIORITY JOURNAL; THYROID CELL; THYROID FOLLICULAR CARCINOMA; WESTERN BLOTTING; ADENOCARCINOMA; BIOASSAY; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; FLOW CYTOMETRY; METABOLISM; PATHOLOGY; SYNTHESIS; THYROID TUMOR; TIME; TUMOR CELL LINE;

ADENOCARCINOMA, FOLLICULAR; APOPTOSIS; BIOLOGICAL ASSAY; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FLOW CYTOMETRY; GALACTOSE; HUMANS; NITRIC OXIDE; NITROARGININE; THYROID NEOPLASMS; TIME FACTORS;

EID: 70149120141     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21876     Document Type: Article

References (35)

1. Avontuur JA, Buijk SL, Bruining HA. 1998. Distribution and metabolism of N(G)-nitro-Larginine methyl ester in patients with septic shock. Eur J Clin Pharmacol 54:627-631.
2. Baldwin SA. 1993. Mammalian passive glucose transporters: Members of an ubiquitous family of active and passive transport proteins. Biochim Biophys Acta 1154:17-49. (Pubitemid 23171388)
3. Bian K, Ke Y, Kamisaki Y, Murad F. 2006. Proteomic modification by nitric oxide. J Pharmacol Sci 101:271-279.
4. Bonina F, Puglia C, Rimoli MG, Melisi D, Boatto G, Nieddu M, Calignano A, La Rana G, De Caprariis P. 2003. Glycosyl derivatives of dopamine and L-dopa as anti-Parkinson prodrugs: Synthesis, pharmacological activity and in vitro stability studies. J Drug Target 11:25-36. (Pubitemid 36527393)
5. Choe W, Kim S, Hwang TS, Lee SS. 2003. Expression of inducible nitric oxide synthase in thyroid neoplasms: Immunohistochemical and molecular analysis. Pathol Int 53:434-439. (Pubitemid 37000044)
6. Closs EI, Gräf P. 1999. Cationic amino acid transporters (CATs). Targets for the manipulation of NO-synthase activity? In: Amidon G, Sadèe W, editors. Membrane transporters as drug targets. New York: Kluwer Academic/Plenum Publishers. pp. 229-249.
7. Coulter JA, McCarthy HO, Xiang J, Roedl W, Wagner E, Robson T, Hirst DG. 2008. Nitric oxide-A novel therapeutic for cancer. Nitric Oxide 19:192-198.
8. Donckier JE, Michel L, Delos M, Havaux X, Van Beneden R. 2006. Interrelated overexpression of endothelial and inducible nitric oxide synthases, endothelin-1 and angiogenic factors in human papillary thyroid carcinoma. Clin Endocrinol 64:703-710. (Pubitemid 43775011)
9. Fitzpatrick B, Mehibel M, Cowen RL, Stratford IJ. 2008. iNOS as a therapeutic target for treatment of human tumors. Nitric Oxide 19:217-224.
10. Gallo O, Masini E, Morbidelli L, Franchi A, Fini-Storchi I, Vergari WA, Ziche M. 1998. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst 90:587-596. (Pubitemid 28204802)
11. Gallo O, Fabbroni V, Sardi I, Magnelli L, Boddi V, Franchi A. 2002. Correlation between nitric oxide and cyclooxygenase-2 pathways in head and neck squamous cell carcinomas. Biochem Biophys Res Commun 299:517-524. (Pubitemid 36034575)
12. Hatanaka M. 1974. Transport of sugars in tumor cell membranes. Biochim Biophys Acta 355:77-104.
13. Hirst D, Robson T. 2007. Targeting nitric oxide for cancer therapy. J Pharm Pharmacol 59: 3-13. (Pubitemid 46133038)
14. Huerta S, Chilka S, Bonavida B. 2008. Nitric oxide donors: Novel cancer therapeutics. Int J Oncol 33:909-927.
15. Kagoura M, Matsui C, Toyoda M, Morohashi M. 2001. Immunohistochemical study of inducible nitric oxide synthase in skin cancers. J Cutan Pathol 28:476-481. (Pubitemid 32881885)
16. Kondo S, Toyokuni S, Tsuruyama T, Ozeki M, Tachibana T, Echizenya M, Hiai H, Onodera H, Imamura M. 2002. Peroxynitrite-mediated stress is associated with proliferation of human metastatic colorectal carcinoma in the liver. Cancer Lett 179:87-93. (Pubitemid 34195657)
17. Kratz F, Müller IA, Ryppa C, Warnecke A. 2008. Prodrug strategies in anticancer chemotherapy. ChemMedChem 3:20-53.
18. Matsuzu K, Segade F, Wong M, Clark OH, Terrier ND, Bowden DW. 2005. Glucose transporters in the thyroid. Thyroid 15:545-550.
19. Melisi D, Secondo A, Montoro P, Piacente S, Rimoli MG, Minale M, de Caprariis P, Annunziato L. 2006. Galactosyl derivatives of L-arginine and D-arginine: Synthesis, stability, cell permeation, and nitric oxide production in pituitary GH3 cells. J Med Chem 49:4826-4833. (Pubitemid 44201041)
20. Mocellin S, Bronte V, Nitti D. 2007. Nitric oxide, a double edged sword in cancer biology: Searching for therapeutic opportunities. Med Res Rev 27:317-352. (Pubitemid 46668937)
21. Nakamura Y, Yasuoka H, Zuo H, Takamura Y, Miyauchi A, Nakamura M, Kakudo K. 2006. Nitric oxide in papillary thyroid carcinoma: Induction of vascular endothelial growth factor D and correlation with lymph node metastasis. J Clin Endocrinol Metab 91:1582-1585.
22. Patel A, Fenton C, Terrell R, Powers PA, Dinauer C, Tuttle RM, Francis GL. 2002. Nitrotyrosine, inducible nitric oxide synthase (iNOS), and endothelial nitric oxide synthase (eNOS) are increased in thyroid tumors from children and adolescents. J Endocrinol Invest 25:675-683.
23. Pervin S, Singh R, Chaudhuri G. 2008. Nitric oxide, N omega-hydroxy-L-arginine and breast cancer. Nitric Oxide 19:103-106.
24. G-nitro-L-arginine. Br J Pharmacol 118:1433-1440.
25. +L activity and transepithelial delivery of NOS inhibitors. FASEB J 19:810-812.
26. Ruocco LA, Viggiano D, Pignatelli M, Iannaccone T, Rimoli MG, Melisi D, Curcio A, De Lucia S, Carboni E, Carnevale UA, de Caprariis P, Sadile AG. 2008a. Galactosylated dopamine increases attention without reducing activity in C57BL/6 mice. Behav Brain Res 187:449-454.
27. Ruocco LA, Viggiano D, Viggiano A, Abignente E, Rimoli MG, Melisi D, Curcio A, Nieddu M, Boatto G, Carboni E, Carnevale UA, Sadile AG. 2008b. Galactosylated dopamine enters into the brain, blocks the mesocorticolimbic system and modulates activity and scanning time in Naples high excitability rats. Neuroscience 152:234-244.
28. Shang ZJ, Li ZB, Li JR. 2006. In vitro effects of nitric oxide synthase inhibitor L-NAME on oral squamous cell carcinoma: A preliminary study. Int J Oral Maxillofac Surg 35:539-543.
29. Shaw RJ. 2006. Glucose metabolism and cancer. Curr Opin Cell Biol 18:598-608.
30. Stanczak A, Ferra A. 2006. Prodrugs and soft drugs. Pharmacol Rep 58:599-613.
31. Strijdom H, Muller C, Lochner A. 2004. Direct intracellular nitric oxide detection in isolated adult cardiomyocytes: Flow cytometric analysis using the fluorescent probe, diaminofluorescein. J Mol Cell Cardiol 37:897-902. (Pubitemid 39222081)
32. Wink DA, Ridnour LA, Hussain SP, Harris CC. 2008. The reemergence of nitric oxide and cancer. Nitric Oxide 19:65-67.
33. Xu W, Liu LZ, Loizidou M, Ahmed M, Charles IG. 2002. The role of nitric oxide in cancer. Cell Res 12:311-320.
34. Yasuda M, Ogane N, Hayashi H, Kameda Y, Miyagi Y, Iida T, Mori Y, Tsukinoki K, Minematsu T, Osamura Y. 2005. Glucose transporter-1 expression in the thyroid gland: Clinicopathological significance for papillary carcinoma. Oncol Rep 14:1499-1504.
35. Yu LB, Dong XS, Sun WZ, Zhao DL, Yang Y. 2005. Effect of a nitric oxide synthase inhibitor NG-nitro-L-argininemethyl ester on invasion of human colorectal cancer cell line SL-174T. World J Gastroenterol 11:6385-6388. (Pubitemid 43014009)